Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Extracellular ubiquitin modulates cardiac fibroblast phenotype and function via its interaction with CXCR4.

Scofield SLC, Daniels CR, Dalal S, Millard JA, Singh M, Singh K.

Life Sci. 2018 Oct 15;211:8-16. doi: 10.1016/j.lfs.2018.09.012. Epub 2018 Sep 5.

PMID:
30195032
2.

Introduction of a process mass intensity metric for biologics.

Budzinski K, Blewis M, Dahlin P, D'Aquila D, Esparza J, Gavin J, Ho SV, Hutchens C, Kahn D, Koenig SG, Kottmeier R, Millard J, Snyder M, Stanard B, Sun L.

N Biotechnol. 2019 Mar 25;49:37-42. doi: 10.1016/j.nbt.2018.07.005. Epub 2018 Aug 16.

PMID:
30121383
3.

Changes in apoptotic gene expression induced by the DNA cross-linkers epichlorohydrin and diepoxybutane in human cell lines.

Silvestri VL, Millard JT.

Data Brief. 2018 May 29;19:932-935. doi: 10.1016/j.dib.2018.05.133. eCollection 2018 Aug.

4.

Cross-linking by epichlorohydrin and diepoxybutane correlates with cytotoxicity and leads to apoptosis in human leukemia (HL-60) cells.

Le PM, Silvestri VL, Redstone SC, Dunn JB, Millard JT.

Toxicol Appl Pharmacol. 2018 Aug 1;352:19-27. doi: 10.1016/j.taap.2018.05.020. Epub 2018 May 21.

PMID:
29792945
5.

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.

Millard J, Pertinez H, Bonnett L, Hodel EM, Dartois V, Johnson JL, Caws M, Tiberi S, Bolhuis M, Alffenaar JC, Davies G, Sloan DJ.

J Antimicrob Chemother. 2018 Jul 1;73(7):1755-1762. doi: 10.1093/jac/dky096.

6.

Polymerase bypass of N7-guanine monoadducts of cisplatin, diepoxybutane, and epichlorohydrin.

Ye J, Farrington CR, Millard JT.

Mutat Res. 2018 May;809:6-12. doi: 10.1016/j.mrfmmm.2018.03.002. Epub 2018 Mar 20.

7.

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM.

Millard JD, Henry J, Rizvi SS, Nelson M.

AIDS. 2016 Aug 24;30(13):2137-9. doi: 10.1097/QAD.0000000000001157. No abstract available.

8.

Understanding of research, genetics and genetic research in a rapid ethical assessment in north west Cameroon.

Kengne-Ouafo JA, Millard JD, Nji TM, Tantoh WF, Nyoh DN, Tendongfor N, Enyong PA, Newport MJ, Davey G, Wanji S.

Int Health. 2016 May;8(3):197-203. doi: 10.1093/inthealth/ihv034. Epub 2015 May 12.

9.

Multidrug resistant tuberculosis.

Millard J, Ugarte-Gil C, Moore DA.

BMJ. 2015 Feb 26;350:h882. doi: 10.1136/bmj.h882. Review. No abstract available.

10.

Assessing the external validity of a randomized controlled trial of anthelminthics in mothers and their children in Entebbe, Uganda.

Millard JD, Muhangi L, Sewankambo M, Ndibazza J, Elliott AM, Webb EL.

Trials. 2014 Aug 6;15:310. doi: 10.1186/1745-6215-15-310.

11.

Application of best practice approaches for designing decision support tools: the preparatory education about clinical trials (PRE-ACT) study.

Fleisher L, Ruggieri DG, Miller SM, Manne S, Albrecht T, Buzaglo J, Collins MA, Katz M, Kinzy TG, Liu T, Manning C, Charap ES, Millard J, Miller DM, Poole D, Raivitch S, Roach N, Ross EA, Meropol NJ.

Patient Educ Couns. 2014 Jul;96(1):63-71. doi: 10.1016/j.pec.2014.04.009. Epub 2014 Apr 21.

12.

Beliefs and practice patterns in spinal manipulation and spinal motion palpation reported by canadian manipulative physiotherapists.

Carlesso LC, Macdermid JC, Santaguida PL, Thabane L, Giulekas K, Larocque L, Millard J, Williams C, Miller J, Chesworth BM.

Physiother Can. 2013 Spring;65(2):167-75. doi: 10.3138/ptc.2012-11.

13.

Case-Study Investigation of Equine Maternity via PCR-RFLP: A Biochemistry Laboratory Experiment.

Millard JT, Chuang E, Lucas JS, Nagy EE, Davis GT.

J Chem Educ. 2013 Nov 12;90(11). doi: 10.1021/ed300740r.

14.

A Web-based communication aid for patients with cancer: the CONNECT Study.

Meropol NJ, Egleston BL, Buzaglo JS, Balshem A, Benson AB 3rd, Cegala DJ, Cohen RB, Collins M, Diefenbach MA, Miller SM, Fleisher L, Millard JL, Ross EA, Schulman KA, Silver A, Slater E, Solarino N, Sulmasy DP, Trinastic J, Weinfurt KP.

Cancer. 2013 Apr 1;119(7):1437-45. doi: 10.1002/cncr.27874. Epub 2013 Jan 18.

15.

The relationships among knowledge, self-efficacy, preparedness, decisional conflict, and decisions to participate in a cancer clinical trial.

Miller SM, Hudson SV, Egleston BL, Manne S, Buzaglo JS, Devarajan K, Fleisher L, Millard J, Solarino N, Trinastic J, Meropol NJ.

Psychooncology. 2013 Mar;22(3):481-9. doi: 10.1002/pon.3043. Epub 2012 Feb 14.

16.

Diepoxybutane interstrand cross-links induce DNA bending.

Millard JT, McGowan EE, Bradley SQ.

Biochimie. 2012 Feb;94(2):574-7. doi: 10.1016/j.biochi.2011.07.030. Epub 2011 Aug 4.

17.

Positive emotionality is associated with baseline metabolism in orbitofrontal cortex and in regions of the default network.

Volkow ND, Tomasi D, Wang GJ, Fowler JS, Telang F, Goldstein RZ, Alia-Klein N, Woicik P, Wong C, Logan J, Millard J, Alexoff D.

Mol Psychiatry. 2011 Aug;16(8):818-25. doi: 10.1038/mp.2011.30. Epub 2011 Apr 12.

18.

Drug therapies for Parkinson's disease: A database analysis of patient compliance and persistence.

Tarrants ML, Denarié MF, Castelli-Haley J, Millard J, Zhang D.

Am J Geriatr Pharmacother. 2010 Aug;8(4):374-83. doi: 10.1016/j.amjopharm.2010.08.001.

PMID:
20869623
19.

What is the emotional acceptance after limb salvage with an expandable prosthesis?

Henderson ER, Pepper AM, Marulanda GA, Millard JD, Letson GD.

Clin Orthop Relat Res. 2010 Nov;468(11):2933-8. doi: 10.1007/s11999-010-1456-8.

20.

Barriers to participation in cancer prevention clinical trials.

Hall MJ, Egleston B, Miller SM, Buzaglo JS, Millard J, Ridgway C, Damjanov N, Sprandio JD, Meropol NJ.

Acta Oncol. 2010 Aug;49(6):757-66. doi: 10.3109/0284186X.2010.485209.

21.

DNA interstrand cross-linking activity of (1-Chloroethenyl)oxirane, a metabolite of beta-chloroprene.

Wadugu BA, Ng C, Bartley BL, Rowe RJ, Millard JT.

Chem Res Toxicol. 2010 Jan;23(1):235-9. doi: 10.1021/tx9003769.

22.

Quantitative PCR analysis of diepoxybutane and epihalohydrin damage to nuclear versus mitochondrial DNA.

Lariviere FJ, Newman AG, Watts ML, Bradley SQ, Juskewitch JE, Greenwood PG, Millard JT.

Mutat Res. 2009 May 12;664(1-2):48-54. doi: 10.1016/j.mrfmmm.2009.02.004. Epub 2009 Feb 21.

23.

Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).

Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D; EPIC (CCR100136) study team.

HIV Med. 2009 Feb;10(2):116-24. doi: 10.1111/j.1468-1293.2008.00660.x.

24.

VEGF and odontoblast-like cells: stimulation by low frequency ultrasound.

Scheven BA, Man J, Millard JL, Cooper PR, Lea SC, Walmsley AD, Smith AJ.

Arch Oral Biol. 2009 Feb;54(2):185-91. doi: 10.1016/j.archoralbio.2008.09.008. Epub 2008 Nov 5.

PMID:
18980757
25.

Lidar system model for use with path obscurants and experimental validation.

Giles JW, Bankman IN, Sova RM, Morgan TR, Duncan DD, Millard JA, Green WJ, Marcotte FJ.

Appl Opt. 2008 Aug 1;47(22):4085-93.

PMID:
18670566
26.

Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.

Currier J, Lazzarin A, Sloan L, Clumeck N, Slims J, McCarty D, Steel H, Kleim JP, Bonny T, Millard J; ASCENT study team.

Antivir Ther. 2008;13(2):297-306.

PMID:
18505181
27.

Using health communication best practices to develop a web-based provider-patient communication aid: the CONNECT study.

Fleisher L, Buzaglo J, Collins M, Millard J, Miller SM, Egleston BL, Solarino N, Trinastic J, Cegala DJ, Benson AB 3rd, Schulman KA, Weinfurt KP, Sulmasy D, Diefenbach MA, Meropol NJ.

Patient Educ Couns. 2008 Jun;71(3):378-87. doi: 10.1016/j.pec.2008.02.017. Epub 2008 Apr 15.

28.

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).

Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, Kabeya K, Clumeck N.

Antimicrob Agents Chemother. 2008 Mar;52(3):858-65. Epub 2007 Dec 10.

29.

An Internet method to assess cancer patient information needs and enhance doctor-patient communication: a pilot study.

Buzaglo JS, Millard JL, Ridgway CG, Ross EA, Antaramian SP, Miller SM, Meropol NJ.

J Cancer Educ. 2007 Winter;22(4):233-40.

PMID:
18067435
30.

VASER-assisted high-definition liposculpture.

Hoyos AE, Millard JA.

Aesthet Surg J. 2007 Nov-Dec;27(6):594-604. doi: 10.1016/j.asj.2007.08.007.

PMID:
19341688
31.

Barriers to clinical trial participation as perceived by oncologists and patients.

Meropol NJ, Buzaglo JS, Millard J, Damjanov N, Miller SM, Ridgway C, Ross EA, Sprandio JD, Watts P.

J Natl Compr Canc Netw. 2007 Sep;5(8):655-64.

PMID:
17927923
32.
33.

Short-term in vitro effects of low frequency ultrasound on odontoblast-like cells.

Scheven BA, Millard JL, Cooper PR, Lea SC, Walmsley AD, Smith AJ.

Ultrasound Med Biol. 2007 Sep;33(9):1475-82. Epub 2007 May 24.

PMID:
17531373
34.

DNA interstrand cross-linking by epichlorohydrin.

Romano KP, Newman AG, Zahran RW, Millard JT.

Chem Res Toxicol. 2007 May;20(5):832-8. Epub 2007 Apr 19.

35.

Differential activation of NF-kappaB and gene expression in oral epithelial cells by periodontal pathogens.

Milward MR, Chapple IL, Wright HJ, Millard JL, Matthews JB, Cooper PR.

Clin Exp Immunol. 2007 May;148(2):307-24. Epub 2007 Mar 9.

36.

The desired future of nursing doesn't just happen--engaged nurses create it.

Capuano T, Drexinger Durishin L, Millard JL, Hitchings KS.

J Nurs Adm. 2007 Feb;37(2):61-3. No abstract available.

PMID:
17273023
37.

Free inferior gluteal flap harvest with sparing of the posterior femoral cutaneous nerve.

Zenn MR, Millard JA.

J Reconstr Microsurg. 2006 Oct;22(7):509-12.

PMID:
17048132
38.

Mesenchymal hamartoma of the liver: is biopsy always necessary?

Millard J, Fraser N, Stewart RJ.

Pediatr Surg Int. 2006 Jul;22(7):622-5. Epub 2006 Jun 8. No abstract available.

PMID:
16807720
39.

Usability testing to improve functionality and content for a web-based provider-patient communication tool.

Fleisher L, Millard J, Raivitch S, Antaramian S, Collins M, Meropol NJ.

AMIA Annu Symp Proc. 2005:956. No abstract available.

40.

The 5'-GNC site for DNA interstrand cross-linking is conserved for diepoxybutane stereoisomers.

Millard JT, Hanly TC, Murphy K, Tretyakova N.

Chem Res Toxicol. 2006 Jan;19(1):16-9.

41.

Molecular evidence from Ciona intestinalis for the evolutionary origin of vertebrate sensory placodes.

Mazet F, Hutt JA, Milloz J, Millard J, Graham A, Shimeld SM.

Dev Biol. 2005 Jun 15;282(2):494-508.

42.

A survey of the use of self-acupuncture in pain clinics--a safe way to meet increasing demand?

Orpen M, Harvey G, Millard J.

Acupunct Med. 2004 Sep;22(3):137-40.

PMID:
15551938
43.

DNA interstrand cross-linking by a mycotoxic diepoxide.

Millard JT, Katz JL, Goda J, Frederick ED, Pierce SE, Speed TJ, Thamattoor DM.

Biochimie. 2004 Jun;86(6):419-23.

PMID:
15358058
44.

A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.

Wood R, Eron J, Arasteh K, Teofilo E, Trepo C, Livrozet JM, Yeo J, Millard J, Wire MB, Naderer OJ.

Clin Infect Dis. 2004 Aug 15;39(4):591-4. Epub 2004 Jul 26.

PMID:
15356829
45.

Flanking sequences modulate diepoxide and mustard cross-linking efficiencies at the 5'-GNC site.

Sawyer GA, Frederick ED, Millard JT.

Chem Res Toxicol. 2004 Aug;17(8):1057-63.

PMID:
15310237
46.

Nurse prescribing: a case for clinical supervision.

Jukes M, Millard J, Chessum C.

Br J Community Nurs. 2004 Jul;9(7):291-7.

PMID:
15284671
47.

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.

Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG.

J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):22-32.

PMID:
14707788
48.

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.

Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ.

Antimicrob Agents Chemother. 2004 Jan;48(1):116-23.

49.

Pax gene expression in the developing central nervous system of Ciona intestinalis.

Mazet F, Hutt JA, Millard J, Shimeld SM.

Gene Expr Patterns. 2003 Dec;3(6):743-5.

PMID:
14643682

Supplemental Content

Loading ...
Support Center